Bipolar Disorder
Bipolar Disorder, previously known as manic depression, is a mental illness characterized by intense mood swings between emotional highs (mania or hypomania) and lows (depression), significantly impacting behavior, energy, and activity levels. During manic phases, individuals exhibit elevated moods, impulsivity, and reduced need for sleep, while depressive phases are marked by feelings of sadness, hopelessness, and high suicide risk, often associated with other mental health issues such as anxiety and substance use disorders.
Health Outcomes
- Alleviated Depression
- Altered Brain Activity to Negative Emotional Stimuli
- Altered Catecholamine Level
- Altered Monoamine Signaling
- Changed Functional Connectivity
- Elevated Serum Tryptophan Levels
- Enhanced BDNF-TrkB Signaling
- Enhanced Brain-Derived Neurotrophic Factor Levels
- Enhanced Neuropharmacological Function
- Enhanced Orbitofrontal Cortex Activation
- Enhanced Reward Responsiveness
- Enhanced Sensory Perception
- Improved Behavioral Abnormalities
- Improved Behavioral Elements
- Improved Brain-Derived Neurotrophic Factor Level
- Improved Cognitive Flexibility
- Improved Coping Strategies
- Improved Depressive Symptoms
- Improved Depressive-Like Behaviours
- Improved Emotional Behavior
- Improved Emotional Well-Being Quality of Life
- Improved Emotional Well-being
- Improved General Behavioral Scores
- Improved Global Clinical Impression
- Improved Medication Adherence
- Improved Mental Health
- Improved Mood Disturbance
- Improved Neuropsychiatric Outcomes
- Improved Neurotransmitter Metabolism
- Improved Perceived Mental Well-being
- Improved Positive Mood States
- Improved Problem-Solving Skills
- Improved Psychological Well-being
- Improved Psychosocial Domain Score
- Improved Psychosocial Health-Related Quality of Life
- Improved Role Emotional
- Improved Set Shifting Ability
- Improved Set-Shifting Reaction Time
- Improved Social Functioning Quality of Life
- Improved Synaptic Plasticity
- Improved Temperament
- Improved Therapeutic Consistency
- Improved Treatment Compliance
- Increased Appetite
- Increased BDNF Levels in the Prefrontal Cortex
- Increased Brain Choline Level
- Increased Brain GABA Levels
- Increased Brain-derived Neurotrophic Factor Level
- Increased Distractibility
- Increased Irritability
- Increased Locomotor Activity During Active Phase
- Increased Myo-Inositol Level
- Increased Plasma Kynurenic Acid Levels
- Increased Plasma Serotonin Levels
- Increased Prefrontal Cortex Deoxygenated Hemoglobin Level
- Increased Production of Beneficial Neurotransmitter GABA
- Increased Serotonin 2A Receptor Levels
- Increased Serotonin Production
- Increased Serum BDNF Levels
- Maintained Normal Behavior
- Modulated HPA Axis
- Modulated Signal Transduction Pathways
- Neutral Blood Profile Impact
- No Adverse Effects on Food Intake
- No CYP1A2 or CYP3A4 Interaction
- No Change in Plasma GABA Levels
- No Significant Difference Compared to Placebo
- Normalized Neurotransmitter Levels
- Reduced ADAM Symptomatology Score
- Reduced Adherence Attrition
- Reduced Agitation
- Reduced Anger
- Reduced Anhedonia
- Reduced Anthranilic Acid Level
- Reduced Behavioral Symptoms
- Reduced Brain Inflammation
- Reduced Depression Scores at Follow-Up
- Reduced Depressive Affect
- Reduced Depressive Behavior
- Reduced Depressive Thoughts
- Reduced Despair-Like Behavior
- Reduced Disturbed Sleep Night
- Reduced Episode Frequency
- Reduced Gut Bacteria Associated with Mental Illness
- Reduced Hamilton Depression Rating Scale Score
- Reduced Impulsivity
- Reduced Indoleamine 2,3-Dioxygenase Activity
- Reduced Irritability
- Reduced Kynurenine Level
- Reduced Mania Symptoms
- Reduced Mood Disturbance
- Reduced Mood Lability
- Reduced N-acetylaspartate Level
- Reduced Negative Mood States
- Reduced Occurrence of Major Depressive Disorder
- Reduced Prefrontal Cortex Activation
- Reduced Prefrontal Cortex Oxygenated Hemoglobin
- Reduced Psychological Distress
- Reduced Psychological Score
- Reduced Psychopathology Symptoms
- Reduced Psychosocial Symptom
- Reduced Relapse Rate
- Reduced Serum BDNF Levels
- Reduced Serum Glutamate Levels
- Reduced Set-Shifting Reversal Error
- Reduced Stroop Reaction Time
- Reduced Sympathetic Nerve Activity
- Reduced Total Side Effects Incidence
- Reduced Treatment Discontinuation
- Regulation of Neuroactive Ligand Receptor Interaction Pathway
- Stabilized Dopamine Pathway Function
- Worsened Depression Score